Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney

Carla Zoja, Norberto Perico, Daniela Corna, Ariela Benigni, Maurizio Gabanelli, Marina Morigi, Tullio Bertani, Giuseppe Remuzzi

Research output: Contribution to journalArticle

Abstract

Previous studies have demonstrated that inhibition of thromboxane A2-dependent platelet aggregation by the thromboxane A2 synthase inhibitor, OKY 1581, ameliorated the progressive kidney disease of rats with subtotal renal ablation. OKY 1581 also decreased the excessive renal thromboxane A2 synthesis and lowered systemic blood pressure. In the same model, a low dose aspirin and a specific thromboxane A2 receptor antagonist failed to influence proteinuria, glomerulosclerosis, and hypertension, thus excluding a role for either platelet or renal thromboxane A2 in renal disease progression. The aims of this study were to establish (1) whether a thromboxane A2 synthase inhibitor different from OKY 1581 could retard the progression of glomerular disease in rats with remnant kidney and (2) whether this effect was associated with an increase in renal synthesis of the vasodilatory prostacyclin. Treatment of rats with renal mass ablation with FCE 22178 (100 mg/kg by gavage and 200 mg/kg in the drinking water) for 35 days starting 10 days after surgical ablation was associated with an improvement in renal function in comparison with rats receiving the vehicle alone. Proteinuria was significantly lower, and rats were partially protected from the development of glomerulosclerosis. Systolic blood pressure was significantly lower than in animals given the vehicle. Urinary thromboxane B2 excretion was significantly decreased, and urinary 6-keto-prostaglandin F increased in respect to vehicle-treated rats. We conclude that FCE 22178 limits glomerular injury in rats with remnant kidney.

Original languageEnglish
Pages (from-to)799-807
Number of pages9
JournalJournal of the American Society of Nephrology
Volume1
Issue number5
Publication statusPublished - Nov 1990

Fingerprint

Thromboxanes
Epoprostenol
Disease Progression
Thromboxane A2
Kidney
Blood Pressure
Proteinuria
Prostaglandin H2 Receptors Thromboxane A2
Thromboxane B2
Kidney Diseases
Platelet Aggregation
Drinking Water
Aspirin
Blood Platelets
Hypertension
Wounds and Injuries

Keywords

  • Glomerular filtration rate
  • Glomerulosclerosis
  • Proteinuria
  • Renal plasma flow
  • Systemic hypertension

ASJC Scopus subject areas

  • Nephrology

Cite this

@article{8550f1745dc14fbeb98d1b8d56a517dc,
title = "Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney",
abstract = "Previous studies have demonstrated that inhibition of thromboxane A2-dependent platelet aggregation by the thromboxane A2 synthase inhibitor, OKY 1581, ameliorated the progressive kidney disease of rats with subtotal renal ablation. OKY 1581 also decreased the excessive renal thromboxane A2 synthesis and lowered systemic blood pressure. In the same model, a low dose aspirin and a specific thromboxane A2 receptor antagonist failed to influence proteinuria, glomerulosclerosis, and hypertension, thus excluding a role for either platelet or renal thromboxane A2 in renal disease progression. The aims of this study were to establish (1) whether a thromboxane A2 synthase inhibitor different from OKY 1581 could retard the progression of glomerular disease in rats with remnant kidney and (2) whether this effect was associated with an increase in renal synthesis of the vasodilatory prostacyclin. Treatment of rats with renal mass ablation with FCE 22178 (100 mg/kg by gavage and 200 mg/kg in the drinking water) for 35 days starting 10 days after surgical ablation was associated with an improvement in renal function in comparison with rats receiving the vehicle alone. Proteinuria was significantly lower, and rats were partially protected from the development of glomerulosclerosis. Systolic blood pressure was significantly lower than in animals given the vehicle. Urinary thromboxane B2 excretion was significantly decreased, and urinary 6-keto-prostaglandin F1α increased in respect to vehicle-treated rats. We conclude that FCE 22178 limits glomerular injury in rats with remnant kidney.",
keywords = "Glomerular filtration rate, Glomerulosclerosis, Proteinuria, Renal plasma flow, Systemic hypertension",
author = "Carla Zoja and Norberto Perico and Daniela Corna and Ariela Benigni and Maurizio Gabanelli and Marina Morigi and Tullio Bertani and Giuseppe Remuzzi",
year = "1990",
month = "11",
language = "English",
volume = "1",
pages = "799--807",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "5",

}

TY - JOUR

T1 - Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney

AU - Zoja, Carla

AU - Perico, Norberto

AU - Corna, Daniela

AU - Benigni, Ariela

AU - Gabanelli, Maurizio

AU - Morigi, Marina

AU - Bertani, Tullio

AU - Remuzzi, Giuseppe

PY - 1990/11

Y1 - 1990/11

N2 - Previous studies have demonstrated that inhibition of thromboxane A2-dependent platelet aggregation by the thromboxane A2 synthase inhibitor, OKY 1581, ameliorated the progressive kidney disease of rats with subtotal renal ablation. OKY 1581 also decreased the excessive renal thromboxane A2 synthesis and lowered systemic blood pressure. In the same model, a low dose aspirin and a specific thromboxane A2 receptor antagonist failed to influence proteinuria, glomerulosclerosis, and hypertension, thus excluding a role for either platelet or renal thromboxane A2 in renal disease progression. The aims of this study were to establish (1) whether a thromboxane A2 synthase inhibitor different from OKY 1581 could retard the progression of glomerular disease in rats with remnant kidney and (2) whether this effect was associated with an increase in renal synthesis of the vasodilatory prostacyclin. Treatment of rats with renal mass ablation with FCE 22178 (100 mg/kg by gavage and 200 mg/kg in the drinking water) for 35 days starting 10 days after surgical ablation was associated with an improvement in renal function in comparison with rats receiving the vehicle alone. Proteinuria was significantly lower, and rats were partially protected from the development of glomerulosclerosis. Systolic blood pressure was significantly lower than in animals given the vehicle. Urinary thromboxane B2 excretion was significantly decreased, and urinary 6-keto-prostaglandin F1α increased in respect to vehicle-treated rats. We conclude that FCE 22178 limits glomerular injury in rats with remnant kidney.

AB - Previous studies have demonstrated that inhibition of thromboxane A2-dependent platelet aggregation by the thromboxane A2 synthase inhibitor, OKY 1581, ameliorated the progressive kidney disease of rats with subtotal renal ablation. OKY 1581 also decreased the excessive renal thromboxane A2 synthesis and lowered systemic blood pressure. In the same model, a low dose aspirin and a specific thromboxane A2 receptor antagonist failed to influence proteinuria, glomerulosclerosis, and hypertension, thus excluding a role for either platelet or renal thromboxane A2 in renal disease progression. The aims of this study were to establish (1) whether a thromboxane A2 synthase inhibitor different from OKY 1581 could retard the progression of glomerular disease in rats with remnant kidney and (2) whether this effect was associated with an increase in renal synthesis of the vasodilatory prostacyclin. Treatment of rats with renal mass ablation with FCE 22178 (100 mg/kg by gavage and 200 mg/kg in the drinking water) for 35 days starting 10 days after surgical ablation was associated with an improvement in renal function in comparison with rats receiving the vehicle alone. Proteinuria was significantly lower, and rats were partially protected from the development of glomerulosclerosis. Systolic blood pressure was significantly lower than in animals given the vehicle. Urinary thromboxane B2 excretion was significantly decreased, and urinary 6-keto-prostaglandin F1α increased in respect to vehicle-treated rats. We conclude that FCE 22178 limits glomerular injury in rats with remnant kidney.

KW - Glomerular filtration rate

KW - Glomerulosclerosis

KW - Proteinuria

KW - Renal plasma flow

KW - Systemic hypertension

UR - http://www.scopus.com/inward/record.url?scp=0025509112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025509112&partnerID=8YFLogxK

M3 - Article

C2 - 2133429

AN - SCOPUS:0025509112

VL - 1

SP - 799

EP - 807

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 5

ER -